文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

MECOM通过功能竞争GATA2促进白血病进展并抑制肥大细胞分化

MECOM promotes leukemia progression and inhibits mast cell differentiation through functional competition with GATA2.
PubMed 文献 · Leukemia · 2026-05-05

该研究揭示MECOM的C端锌指结构域是其主要DNA结合模块,疾病相关突变可消除其DNA结合能力。MECOM通过C端锌指结构域介导的DNA结合并招募共抑制因子CtBP,功能性拮抗GATA2,从而促进髓系白血病发生并抑制肥大细胞分化。所构建的C端锌指结构域突变敲入小鼠模型重现了MECOM相关综合征的临床表型。

要点

  • MECOM的C端锌指结构域是主要DNA结合模块,疾病相关突变导致DNA结合能力丧失。
  • MECOM通过C端锌指结构域结合DNA并招募CtBP,功能性拮抗GATA2。
  • 该拮抗作用促进髓系白血病发生并抑制肥大细胞分化。

核心结论

  • C端锌指结构域突变为功能丧失性突变,损害DNA结合能力。
  • MECOM-GATA2轴是白血病发生和肥大细胞分化的关键调控通路。

研究设计与样本

  • 基础实验研究结合敲入小鼠模型,携带C端锌指结构域突变。

主要发现

  • MECOM的C端锌指结构域为优势DNA结合模块,疾病相关突变消除其DNA结合能力。
  • MECOM通过C端锌指结构域介导DNA结合并招募共抑制因子CtBP,功能性拮抗GATA2。
  • 该拮抗作用促进髓系白血病发生并抑制肥大细胞分化。
  • C端锌指结构域突变敲入小鼠重现MECOM相关综合征临床表型,包括造血干细胞和B细胞减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MECOM is a transcription factor critical for the maintenance of hematopoietic stem cells (HSCs) and the pathogenesis of myeloid leukemia. Germline mutations clustered in the C-terminal zinc finger domain (ZFD) of MECOM are known to cause MECOM-associated syndromes, involving bone marrow failure and skeletal anomalies. However, the molecular consequences of these mutations and the precise downstream mechanisms of MECOM remain elusive. Here, we demonstrate that the C-terminal ZFD serves as the dominant DNA-binding module of MECOM, and that disease-associated mutations abrogate its DNA-binding capacity. Mechanistically, we reveal that MECOM functionally antagonizes GATA2 via C-terminal ZFD-mediated DNA binding and recruitment of the corepressor CtBP. This repression promotes myeloid leukemogenesis while suppressing mast cell differentiation. Furthermore, we generated a knockin mouse model harboring a C-terminal ZFD mutation, which successfully recapitulated the clinical phenotypes of MECOM-associated syndromes, including reduction of HSCs and B cells. Collectively, our findings define C-terminal ZFD mutations as loss-of-function mutations with impaired DNA binding, uncover the MECOM-GATA2 axis as a key regulatory pathway, and provide a valuable mouse model for understanding MECOM-associated syndromes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Iida K, Nakanishi M, Nakahara J, et al. MECOM promotes leukemia progression and inhibits mast cell differentiation through functional competition with GATA2. Leukemia. 2026. PMID: 42086934. doi:10.1038/s41375-026-02977-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。